Physician profile
Xue Yang
NPI 1487190153
$1,480.05
in general payments reported to CMS, 2019-2025
24 companies · $15.97 in 2025
The $15.97 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $547 · 2023: $329 · 2024: $74.62 · 2025: $15.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $162.34 | 2022 | |
| Novo Nordisk INC | $153.57 | 2021-2023 | Ozempic |
| Merck Sharp & Dohme LLC | $142.66 | 2021-2023 | Dificid |
| Astrazeneca Pharmaceuticals LP | $121.61 | 2022 | |
| Abbvie INC. | $118.26 | 2021-2024 | |
| Genzyme Corporation | $86.26 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $83.31 | 2021 | |
| Pfizer INC. | $78.90 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.81 | 2021-2023 | Tradjenta, Jardiance |
| Novartis Pharmaceuticals Corporation | $58.94 | 2021-2024 | |
| Lilly USA, LLC | $55.19 | 2021-2023 | Mounjaro |
| Cranial Technologies, INC | $52.34 | 2021-2022 | |
| Glaxosmithkline, LLC. | $52.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.89 | 2022-2023 | Xifaxan |
| Incyte Corporation | $39.31 | 2023 | Opzelura, Iclusig |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $30.44 | 2021 | |
| Hologic Sales and Service, LLC | $26.76 | 2021 | |
| Kci USA, INC. | $21.40 | 2023 | Activ.A.C. |
| Amgen INC. | $15.97 | 2025 | Repatha, Otezla |
| Janssen Biotech, INC. | $15.59 | 2023 | Tremfya |
| Evofem Biosciences, INC. | $14.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.36 | 2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $11.91 | 2022 | |
| Organon LLC | $10.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xue Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.